NLS Pharmaceutics Plunges 16.78% Post Reverse Split

On July 2, 2025, NLS Pharmaceutics experienced a significant drop of 16.78% in pre-market trading, marking a notable decline in its stock performance.

NLS Pharmaceutics recently completed a 1 for 40 reverse stock split, which means shareholders now hold one share for every 40 shares they previously owned. This move is often undertaken to boost the stock price and attract more investors, but it can also lead to volatility in the short term.

In June 2025, NLS Pharmaceutics successfully closed a $1 million equity financing round, bringing the total gross proceeds from equity financing to $3 million. This funding is crucial for the company's ongoing operations and future growth initiatives.

On June 30, 2025, NLS Pharmaceutics held an extraordinary shareholders' meeting where all proposed agenda items were approved. This indicates strong support from shareholders and a clear direction for the company's strategic plans.

NLS Pharmaceutics has extended its merger agreement, signaling continued efforts to consolidate and strengthen its market position. This development is part of the company's broader strategy to enhance its competitive edge and drive long-term growth.